Robert A. Galemmo

LRRK2 secretion in exosomes is regulated by 14-3-3

K. B. Fraser, Mark S. Moehle, João Paulo Lima Daher et al. · Human Molecular Genetics · 2013 · 164 citations · Full text

Protein Secretion, Pathology, Extracellular Microvesicles +17

Structure-Based Design of Novel Guanidine/Benzamidine Mimics:  Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants

Patrick Y. S. Lam, Charles G. Clark, Renhua Li et al. · Journal of Medicinal Chemistry · 2003 · 95 citations · Full text

Pharmaceutical Science, Oral Bioavailability, Pharmacotherapy +18

Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-<i>N</i>- [3-fluoro-2‘-(aminosulfonyl)[1,1‘-biphenyl)]-4-yl]-1<i>H</i>-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

James R. Pruitt, Donald Pinto, Robert A. Galemmo et al. · Journal of Medicinal Chemistry · 2003 · 75 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Chemical Biology +18

The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: A new class of Aurora-A kinase inhibitors

K.J.M. Moriarty, Holly K. Koblish, Thomas Garrabrant et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 64 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Biochemistry +7

1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa

Donald Pinto, Michael J. Orwat, Mimi L. Quan et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 63 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Science +11